title: Osteoporosis in 2011: Osteoporosis therapy--dawn of the post-bisphosphonate era.
abstract: Over the past decade, investigators have actively searched for safer therapeutic approaches to replace or complement the use of bisphosphonates and/or parathyroid hormone, exploring both antiresorptive and osteoanabolic pathways. Besides marked progress in basic research, the year 2011 has seen several compounds for the treatment of osteoporosis enter or progress within clinical trials.
authors.affiliation: Department of Medicine, Harvard Medical School, Massachusetts General Hospital, Endocrine Unit, 188 Longwood Avenue, Boston, MA 02115, USA. roland_baron@hms.harvard.edu
authors.forename: Roland
authors.initials: R
authors.lastname: Baron
mesh_terms: D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D004704:Endocrinology / Q000379:methods / Q000639:trends*; D006801:Humans; D010024:Osteoporosis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D010281:Parathyroid Hormone / Q000627:therapeutic use; D056737:Safety-Based Drug Withdrawals / Q000379:methods / Q000458:organization & administration; D013997:Time Factors
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D010281:Parathyroid Hormone